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Purpose: To investigate the effect of computed tomography (CT) using hepatic arterial phase (HAP) and portal
venous phase (PVP) contrast on dose calculation of stereotactic body radiation therapy (SBRT) for liver cancer.
Methods: Twenty-one patients with liver cancer were studied. HAP, PVP and non-enhanced CTs were performed
on subjects scanned in identical positions under active breathing control (ABC). SBRT plans were generated using
seven-field three-dimensional conformal radiotherapy (7 F-3D-CRT), seven-field intensity-modulated radiotherapy
(7 F-IMRT) and single-arc volumetric modulated arc therapy (VMAT) based on the PVP CT. Plans were copied to the
HAP and non-enhanced CTs. Radiation doses calculated from the three phases of CTs were compared with respect
to the planning target volume (PTV) and the organs at risk (OAR) using the Friedman test and the Wilcoxon signed
ranks test.
Results: SBRT plans calculated from either PVP or HAP CT, including 3D-CRT, IMRT and VMAT plans, demonstrated
significantly lower (p <0.05) minimum absorbed doses covering 98%, 95%, 50% and 2% of PTV (D98%, D95%,
D50% and D2%) than those calculated from non-enhanced CT. The mean differences between PVP or HAP CT and
non-enhanced CT were less than 2% and 1% respectively. All mean dose differences between the three phases of
CTs for OARs were less than 2%.
Conclusions: Our data indicate that though the differences in dose calculation between contrast phases are not
clinically relevant, dose underestimation (IE, delivery of higher-than-intended doses) resulting from CT using PVP
contrast is larger than that resulting from CT using HAP contrast when compared against doses based upon
non-contrast CT in SBRT treatment of liver cancer using VMAT, IMRT or 3D-CRT.
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Table 1 Basic and clinical characteristics of selected








Primary hepatocellular carcinoma 9 (42.9%)
Metastatic liver cancer 12 (57.1%)
PTV Volume (cm3)
0– < 50 14 (66.7%)
50– < 100 4 (19.0%)
100– < 150 2 (9.5%)
150–200 1 (4.8%)
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Hepatocellular carcinoma (HCC) is the fifth most
common cancer worldwide [1]. Moreover, liver is a
common site for metastases from a variety of primary
malignancies [2]. Generally, surgery is acknowledged
to be the most effective treatment for liver cancer,
though only 20-40% of HCC patients may benefit from
radical therapies [3]. By time of diagnosis only 10-20%
of metastatic liver cancer cases undergo surgical resec-
tion [4]. However, stereotactic body radiation therapy
(SBRT), which includes the application of volumetric
modulated arc therapy (VMAT), has been an import-
ant addition to the arsenal for treatment of liver cancer
[5-7].
SBRT is a technique designed to deliver radiation
precisely to delineated tumor areas. However, tactics
used to define a gross tumor volume (GTV) might
vary significantly among professionals, centers and
levels of experiences [8]. Use of contrast in hepatic ar-
terial phase (HAP) and portal venous phase (PVP)
computed tomography (CT) has improved detection
accuracy in liver cancer [9,10]. However, contrasted
imaging may adversely influence the prescribed SBRT
dose distribution. To quantify the influence of con-
trast on dose calculation, two modes of investigation
have been used. One is based on phantoms, or math-
ematical algorithms, designed to take into account
parameters that include photon beam energies, molar-
ities and contrast agent expansion [11,12]. Human
studies are another mode, and they have revealed a
negligible effect on dose calculation in regions with
low contrast agent penetration [13-15]. However, it
was reported that in treatment of upper abdominal tu-
mors contrast agent is responsible for greater than 2%
increase in monitor units (MUs) of three-dimensional
conformal radiotherapy (3D-CRT) [16], but that the
effect of contrast agent on dose calculation decreased
with an increasing number of incident beams [12].
Since VMAT plans are designed using a larger number
of segments (typically, there are 91 segments in a
single-arc VMAT plan), the effect of contrast agent on
VMAT plans is unknown.
Because liver has a dual blood supply from the hep-
atic artery and portal vein, distribution of contrast
agent should differ between HAP and PVP CTs. It
would then be reasonable to suspect that radiotherapy
plans, based on either HAP or PVP CT, may differ as
well and that dosing errors may result. To our know-
ledge, there are no studies on the effect of different
CT phases for dose calculation of SBRT treatment
plans, especially using VMAT, in liver cancer. We
therefore conducted this study to query the influence
of HAP and PVP CT on dose calculation of SBRT
plans in liver cancer.Material and methods
Eligibility
Twenty-one liver cancer patients were enrolled from a
single institution. Included patients had no more than
three lesions, and liver lesions were no larger than 6 cm
in diameter. All patients were ruled-out for surgical re-
section before being enrolled (Table 1).
Acquisition of CT
Each patient was immobilized in a stereotactic body frame
(SBF, Elekta Oncology System, Sweden) in the supine pos-
ition with arms raised above the head. Patients were
trained to adapt to active breathing control (ABC) before-
hand at moderate deep inspiration breath-hold with 75%
of maximum inspiratory volume. Non-enhanced CT cov-
ering the total liver volume was obtained (Philips Gemini
GXL, 120 kVp, 90 mAs) at 3 mm slice thickness under
ABC. 25–30 seconds after intravenous bolus injection of
120 ml of the contrast agent (Iopamiro370, a non-ionic X-
ray contrast agent; main ingredient: iopamidol 370 mgI/ml,
Bracco S.P.A., Italy) with a power injector at a rate of
4–5 ml/second, the HAP CT was scanned; PVP CT was
obtained 55–60 seconds after the injection.Region of interest contouring
After the image acquisition, CTs obtained in three phases
were transferred to a radiotherapy planning system
(Pinnacle3 9.0, Philips Inc., USA). Representative imaging
demonstrating the three phases is provided in Figure 1.
The GTV and organs at risk (OAR) were delineated
on the PVP CT. GTV was expanded by a 5-mm radial
and a 10-mm cranial-caudal margin to create the
Figure 1 Three phases of CTs for the same patient. Left: portal venous phase (PVP) CT; Middle: hepatic arterial phase (HAP) CT; Right:
non-enhanced CT.
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ach, bowel and kidneys were contoured as the OARs.
Treatment planning
SBRT plans were designed on the PVP CT using 3D-
CRT, IMRT and VMAT respectively for each patient. All
plans were executed using a 6 MV photon beam from a
linear accelerator (Synergy, Elekta, Sweden). The pre-
scription doses were 48 Gy in 4 fractions.
3D-CRT plans were generated using seven coplanar
static-fields. According to the guidance from RTOG 0236
recommendations for lung SBRT, no additional margin at
the edges of the blocks or multi-leaf collimator (MLC)
jaws beyond the PTV was considered. In this study, the
minimum absorbed dose covering 95% of PTV (D95%)
met or exceeded 48 Gy; total patient tissue volume (not
including PTV) receiving ≥110% of the prescription dose
could not exceed 1.0 cm3; liver mean dose (LMD) was less
than 22 Gy; the percentage of right kidney volume receiv-
ing ≥15 Gy (V15) was less than 33%; dose to spinal cord
could not exceed 18 Gy; maximum volume of bowel and
stomach receiving ≥30 Gy (V30) less than 0.5 cm3.
IMRT plans (7 F-IMRT) were generated using the
same fields as the 3D-CRT plans, optimized using Direct
Machine Parameter Optimization (DMPO). Additional
parameters were as follows: the minimum segment area
was 4 cm2; the minimum segment MU was 5; the max-
imum number of segments was 50; total patient tissue
volume receiving ≥110% of the prescription dose could
not exceed 1.0 cm3. Remaining parameters were the
same as in 3D-CRT plans.
VMAT plans were generated using a single arc (181°-
180°). Other parameters were identical to those of the
IMRT plan.
All doses were calculated using a collapsed-cone con-
volution (CC) algorithm with grid size 0.4 × 0.4 ×
0.4 cm3, and all doses were calculated using the electron
densities converted from CT number (HU) based on the
Model 062 M Electron density phantom composed ofeight different tissue equivalent inserts (doses to tissue).
After the completion of plans using PVP CT, prescrip-
tion doses were normalized to MUs. All contours and
plans were copied to the HAP and non-enhanced CTs.
Thereafter, the radiation doses were recalculated.
To verify dose differences caused by contrast agent or
other factors (such as algorithm, inconsistency of patients’
positions, etc.), the density of three phases of CTs (PVP,
HAP and non-enhanced) were specified as the density of
water. Then the doses were recalculated (doses to water).
Statistical analysis
To evaluate the equivalence of the patients’ positions and
coordinates among these CTs after image fusion, Y coordi-
nates (cranial-caudal axis) of the diaphragmatic dome and
the source to surface distances (SSD) were recorded and
analyzed. Dose parameters in the targets and OARs
among these CTs were compared, including the D98%,
D95%, D50%, D2%, heterogeneity index (HI = (D2% -
D98%)/D50%) and conformity index (CI) where CI is
given by the following equation: CI = (TV95% × TV95%)/
(TV ×V95%)) [N.B. TV95% = PTV volume covered by the
95% isodose, TV = PTV, and V95% = volume of the 95%
isodose]. OAR parameters included the D2% of the right
kidney, bowel, stomach and spinal cord; the mean dose of
the liver and right kidney; and the percentage of total liver
volume receiving ≥21 Gy (V21). GTV was excluded from
liver volume. Differences were analyzed by Friedman test
or Wilcoxon signed ranks test (SPSS, Release 17.0). p <
0.05 (2-tailed) indicated statistical significance.
Results
SSD
Differences between SSDs ranged from −8.7 to 8.50 mm
in each beam. Average SSD difference between PVP CT
and non-enhanced CT was 0.23 ± 1.77 mm and for
HAP CT versus non-enhanced CT was 0.28 ± 1.77 mm.
Diaphragmatic dome coordinates differed with a range
of −9.0 to 6.0 mm. Average difference of the diaphragmatic
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non-enhanced CT, and −0.14 ± 4.60 mm for HAP CT vs.
non-enhanced CT. There were no significant differences
among the SSDs or diaphragmatic dome coordinate of
the PVP, HAP and non-enhanced CTs (p > 0.05).
Hounsfield units (HU) representing the GTV and liver
varied significantly (p < 0.05) among the PVP, HAP, and
non-enhanced CTs. HU values for GTV and liver by
imaging phase used, in terms of magnitude, were PVP
CT >HAP CT > non-enhanced CT. The mean differences
of HUs in GTV and liver among three sets of CTs are as
follows: 41.06 ± 24.74 HU and 58.05 ± 17.83 HU for PVP
CT vs. non-enhanced CT, 22.58 ± 17.62 HU and 20.23 ±
22.56 HU for the set of HAP CT vs. non-enhanced CT,
and 18.48 ± 14.65 HU and 37.82 ± 14.82 HU for the
phase of PVP CT vs. HAP CT.
PTV
We calculated significant variation (p < 0.05) in D98%,
D95%, D50% and D2% among PVP-, HAP- and non-
enhanced CT-based plans, regardless of whether 3D-
CRT, IMRT or VMAT was used. D98%, D95%, D50%
and D2% calculated from the three phases of CTs, by
order of magnitude, were as follows: PVP CT <HAP
CT < non-enhanced CT (p < 0.05). Maximum differences
in D98%, D95%, D50% and D2% calculated from the
plans with three phases of CTs were, respectively, 2.75%,
2.66%, 2.94%, 4.00% (PVP CT vs. non-enhanced CT);
2.10%, 2.15%, 2.43%, 2.72% (HAP CT vs. non-enhanced
CT); and 1.93%, 1.86%, 1.90%, 2.99% (PVP CT vs. HAP
CT). Mean differences (MD to tissue), however, were
less at 2% (PVP CT vs. non-enhanced CT), 1% (HAP CT
vs. non-enhanced CT), and 1% (PVP CT vs. HAP CT)
(see Table 2).
OARs
Analysis of doses to OAR shows LMD calculated from ei-
ther PVP or HAP CT was significantly lower than those
from the non-enhanced CT (p < 0.05). However, all mean
differences across the three phases of CT in dose to OARs
was less than 2% (Table 3).
With the density specified as the density of water, the
mean differences in D98%, D95%, D50% and D2% for
PTV (MD to water) among the three phases of CTs were
less than 0.1%; the ratio of MD to water and MD to tis-
sue were less than 6.64%.
Dose differences attributable to the contrast agent
were similar among the three kinds of plans (single arc
VMAT, 7 F-IMRT and 7 F-3D-CRT, p > 0.05) according
to the Friedman test.
Discussion
The liver possesses a dual blood supply from the hepatic
portal vein and hepatic arteries. The hepatic portal veinsupplies approximately 75% of the liver’s blood flow, and
the hepatic artery accounts for the remainder. Moreover,
the liver is the dominant organ for congregation of con-
trast agent. After intravenous bolus injection, contrast
agent transported via hepatic artery arrives 20–30 sec-
onds earlier to the liver than if transported via portal
vein, and this differential explains the difference seen be-
tween HAP and PVP imaging. Studies have confirmed
that utilizing both PVP and HAP CTs elevates the rates
of detection [9,10]. Therefore, the PVP and HAP CTs
are often applied during the simulation stage of liver
cancer radiotherapy treatment. Hounsfield units repre-
sent a tissue’s electron density via x-ray attenuation, and
as such, are a critical and contributory component of
dose calculation in the planning system. In this study,
we found that the HUs of the GTV and liver in both
PVP and HAP CTs were higher than those in the non-
enhanced CT; moreover, the increase of HUs in the PVP
CT was more obvious than that in other phases.
In this study, SSDs varied in patients similarly to our
previous report on lung cancer [13], while there was
more variation than what has been seen on head and
neck cancer [14]. Due to the significant cranial-caudal
displacement of liver resulting from respiratory motion
[17], we assessed the Y-axes coordinates of the diaphrag-
matic dome. Both the mean value and range of the dia-
phragmatic dome’s displacement were much smaller
with ABC than without it. There were no significant dif-
ferences in either SSDs or displacement of the diaphrag-
matic dome among these phases of CTs. Therefore,
patients were considered to have been scanned in nearly
identical positions; the influence of positioning errors
among these CTs was negligible.
Shibamoto et al. reported an increase of 51 ± 17 HU of
enhanced liver CT over non-enhanced. Mean increases
of MUs were more than 2%, and the maximum increase
was 7.6 MU for upper abdominal tumors [16]. In con-
trast to their results, our data showed that in the SBRT
plans, the dose differences to PTV between the PVP and
non-enhanced CTs were lower than 2%; however, the
dose differences to PTV between the HAP and non-
enhanced CTs were lower than 1%. We speculate that
ABC technique explains the divergence. ABC works to
coordinate scanning with cycles in respiratory move-
ment, and thus we feel that our analysis of the treatment
effect of contrast agent in imaging is better assessed
employing the ABC technology. Choi et al. found the
GTV HUs of head and neck increased by an average of
55 HUs, and that PTV doses differed less than 1% (en-
hanced CT vs. non-enhanced CT) [14]. These dose differ-
ences are similar to the dose changes between the HAP
and non-enhanced CTs; however, they are less than the
dose differences between the PVP and non-enhanced CTs
in our study. Here we speculate that this change in dose
Table 2 Comparison of PTV doses calculated from PVP, HAP and non-enhanced CTs
Dp Da Dn P(p,a,n)* (Dn-Dp)/Dn(%) P(p,n)# (Dn-Da)/Dn(%) P(a,n)# (Da-Dp)/Dn(%) P(p,a)#
3D-CRT
CI 0.84 ± 0.07 0.83 ± 0.07 0.83 ± 0.07 0.116 −1.15 ± 2.44 - −0.49 ± 1.72 - −0.66 ± 1.00 -
HI 0.17 ± 0.02 0.17 ± 0.02 0.17 ± 0.02 0.117 1.04 ± 4.84 - −0.50 ± 5.77 - 1.54 ± 4.29 -
D98% (Gy) 46.83 ± 0.28 47.09 ± 0.41 47.36 ± 0.46 0.000 1.12 ± 0.78 0.000 0.56 ± 0.51 0.000 0.56 ± 0.58 0.000
D95% (Gy) 48.09 ± 0.06 48.36 ± 0.29 48.62 ± 0.40 0.000 1.10 ± 0.76 0.000 0.54 ± 0.58 0.000 0.56 ± 0.56 0.000
D50% (Gy) 53.17 ± 0.52 53.52 ± 0.57 53.83 ± 0.75 0.000 1.23 ± 0.81 0.000 0.58 ± 0.54 0.000 0.64 ± 0.56 0.000
D2% (Gy) 55.63 ± 1.14 56.09 ± 1.28 56.39 ± 1.43 0.000 1.33 ± 1.21 0.000 0.53 ± 1.09 0.000 0.81 ± 0.93 0.000
IMRT
CI 0.85 ± 0.04 0.82 ± 0.06 0.79 ± 0.09 0.000 −8.60 ± 9.78 0.000 −4.34 ± 6.09 0.000 −4.25 ± 5.84 0.000
HI 0.05 ± 0.01 0.06 ± 0.01 0.06 ± 0.01 0.040 4.82 ± 8.30 0.006 2.58 ± 5.74 0.070 2.24 ± 5.70 0.111
D98% (Gy) 47.60 ± 0.20 47.85 ± 0.30 48.06 ± 0.45 0.000 0.94 ± 0.68 0.000 0.43 ± 0.49 0.000 0.51 ± 0.43 0.000
D95% (Gy) 48.05 ± 0.08 48.31 ± 0.23 48.54 ± 0.35 0.000 1.01 ± 0.72 0.000 0.46 ± 0.50 0.000 0.55 ± 0.51 0.000
D50% (Gy) 49.24 ± 0.30 49.54 ± 0.43 49.80 ± 0.48 0.000 1.11 ± 0.83 0.000 0.52 ± 0.62 0.000 0.59 ± 0.53 0.000
D2% (Gy) 50.28 ± 0.45 50.61 ± 0.51 50.91 ± 0.60 0.000 1.23 ± 0.99 0.000 0.59 ± 0.74 0.000 0.64 ± 0.66 0.000
VMAT
CI 0.81 ± 0.08 0.79 ± 0.08 0.78 ± 0.10 0.000 −4.93 ± 6.74 0.000 −2.38 ± 4.89 0.002 −2.54 ± 2.91 0.000
HI 0.07 ± 0.02 0.08 ± 0.02 0.08 ± 0.02 0.137 1.92 ± 6.65 - −0.51 ± 4.73 - 2.43 ± 4.11 -
D98% (Gy) 47.45 ± 0.23 47.67 ± 0.32 47.89 ± 0.47 0.000 0.90 ± 0.64 0.000 0.45 ± 0.45 0.000 0.45 ± 0.38 0.000
D95% (Gy) 48.06 ± 0.04 48.28 ± 0.21 48.51 ± 0.31 0.000 0.93 ± 0.66 0.000 0.47 ± 0.42 0.000 0.46 ± 0.44 0.000
D50% (Gy) 49.98 ± 0.41 50.27 ± 0.51 50.52 ± 0.51 0.000 1.06 ± 0.79 0.000 0.49 ± 0.51 0.000 0.58 ± 0.52 0.000
D2% (Gy) 51.19 ± 0.62 51.54 ± 0.76 51.78 ± 0.80 0.000 1.13 ± 0.87 0.000 0.46 ± 0.53 0.000 0.68 ± 0.59 0.000
Abbrevations: PVP, portal venous phase; HAP, hepatic arterial phase. Dp, Da and Dn were the dose calculated from portal venous phase, hepatic arterial phase
and non-enhanced phase CTs respectively. 98%, 95%, 50% and 2%, were the minimum absorbed dose that covers 98%, 95%, 50% and 2% of the volume of the
PTV respectively. CI, the conformity index; HI, the heterogeneity index. *, Friedman test; #, Wilcoxon signed ranks test.
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tion varied in different phases. Moreover HU values by
order of magnitude for GTV and liver were PVP CT >
HAP CT > non-enhanced CT (p < 0.05). Therefore, the
resulting data encourages us to further clarify the effect of
contrast agent application on the dose underestimation
for the plans of radiotherapy.
Ramm et al. had found in a phantom-based study that
the effect of contrast agent decreased with an increase of
the number of incident beams [12]. In Ramm et al’s study,
the plans were created with a single photon beam or two
opposing photon beams or an isocentric four-field box
technique. The number of incident beams was less than
that in our study (VMAT 91 segments; IMRT ≤50 seg-
ments; 3D-CRT 7 beams). Although the VMAT plans had
the most segments or beams, compared with non-
enhanced CT, the dose underestimations attributable to
the contrast agent showed no significant difference across
the three plan types (p > 0.05). It is possible that when the
number of beams or segments increases to a certain
threshold value, the dose effects caused by the contrast
agent will tend to be consistent. This question deserves
further investigation.There was concern that the accuracy of the CC algo-
rithm might affect the accuracy of dose underestimation
in our study. Therefore calibrated ionization chamber
and radiochromic EBT type films in a homogenous poly-
styrene phantom and in heterogeneous lung phantoms
were used for evaluating the accuracy of the algorithm
[18]. The result indicated some small difference between
the CC and Monte Carlo (MC) algorithms in the mea-
surements. Knöös et al. also reported that when the
average dose in the PTV for prostate cases calculated by
the MC was set to 100%, the average dose, D95%, and
D5% of PTV calculated by the Pinnacle CC algorithm
were 100%, 98.2%, and 101.4% respectively [19]. Because
prostatic tissue and liver are similarly homogenous we
believe that the algorithm is translatable from prostate
to liver and that the effect of the algorithm on the dose
calculation for SBRT plans using VMAT or IMRT or 3D
CRT is negligible. The results in this study indicated that
when the density of PVP, HAP, and non-enhanced CTs
were specified as the density of water, the MD-to-water
among three phases of CTs were less than 0.1%, the ratio
of MD-to-water and MD-to-tissue were less than 6.64%.
This finding further confirmed that the dose differences
Table 3 Comparison of OARs’ doses calculated from PVP, HAP and non-enhanced CTs
Dp Da Dn P(p,a,n)* (Dn-Dp)/Dn (%) P(p,n)# (Dn-Da)/Dn (%) P(a,n)# (Da-Dp)/Dn (%) P(p,a)#
3D-CRT
Liver V21 (%) 12.77 ± 11.45 12.87 ± 11.53 12.94 ± 11.55 0.000 1.70 ± 1.50 0.000 0.90 ± 1.20 0.000 0.80 ± 0.85 0.000
Liver Dmean (Gy) 8.52 ± 5.00 8.57 ± 5.03 8.61 ± 5.04 0.000 1.02 ± 0.73 0.000 0.51 ± 0.64 0.000 0.52 ± 0.47 0.000
Right kidney D2%(Gy) 13.59 ± 14.36 13.60 ± 14.35 13.69 ± 14.48 0.000 0.56 ± 1.29 0.000 0.33 ± 1.10 0.001 0.23 ± 0.58 0.140
Right kidney Dmean (Gy) 2.87 ± 3.47 2.87 ± 3.47 2.89 ± 3.50 0.201 −0.09 ± 1.01 - 0.18 ± 0.81 - −0.27 ± 0.53 -
Bowl D2% (Gy) 12.83 ± 8.63 12.84 ± 8.65 12.86 ± 8.72 0.040 −0.31 ± 2.50 0.254 −0.13 ± 2.27 0.074 −0.18 ± 1.13 0.268
Stomach D2% (Gy) 16.42 ± 7.62 16.54 ± 7.66 16.65 ± 7.69 0.000 1.45 ± 2.33 0.003 0.71 ± 1.40 0.004 0.74 ± 1.31 0.001
Spinal cord D2% (Gy) 11.28 ± 6.79 11.31 ± 6.79 11.36 ± 6.81 0.006 0.73 ± 1.38 0.000 0.46 ± 0.88 0.004 0.27 ± 1.06 0.234
IMRT
Liver V21 (%) 25.31 ± 6.90 25.35 ± 6.89 25.39 ± 6.87 0.040 0.38 ± 0.87 0.046 0.19 ± 0.68 0.338 0.19 ± 0.43 0.026
Liver Dmean (Gy) 10.00 ± 4.95 10.05 ± 4.99 10.09 ± 4.99 0.000 0.97 ± 0.77 0.000 0.49 ± 0.74 0.000 0.48 ± 0.46 0.000
Right kidney D2% (Gy) 14.71 ± 14.88 14.71 ± 14.89 14.82 ± 15.02 0.003 0.32 ± 1.22 0.002 0.30 ± 1.21 0.006 0.01 ± 0.50 0.050
Right kidney Dmean (Gy) 3.04 ± 3.12 3.03 ± 3.12 3.06 ± 3.15 0.090 0.02 ± 1.00 - 0.29 ± 0.84 - −0.27 ± 0.54 -
Bowl D2% (Gy) 10.99 ± 6.88 11.02 ± 6.90 11.09 ± 6.93 0.000 0.90 ± 0.86 0.000 0.65 ± 0.88 0.002 0.26 ± 0.69 0.178
Stomach D2% (Gy) 11.73 ± 6.99 11.80 ± 7.03 11.85 ± 7.07 0.000 0.89 ± 1.90 0.012 0.39 ± 1.23 0.008 0.50 ± 1.28 0.002
Spinal cord D2% (Gy) 9.09 ± 4.50 9.12 ± 4.49 9.17 ± 4.50 0.003 0.99 ± 1.64 0.003 0.57 ± 1.13 0.001 0.42 ± 0.95 0.195
VMAT
Liver V21 (%) 20.71 ± 7.27 20.75 ± 7.27 20.77 ± 7.26 0.017 0.35 ± 0.71 0.018 0.14 ± 0.47 0.355 0.21 ± 0.34 0.005
Liver Dmean (Gy) 10.10 ± 5.24 10.16 ± 5.28 10.20 ± 5.29 0.000 0.97 ± 0.67 0.000 0.45 ± 0.59 0.000 0.52 ± 0.43 0.000
Right kidney D2% (Gy) 14.30 ± 14.80 14.33 ± 14.83 14.41 ± 14.87 0.000 0.68 ± 1.08 0.000 0.38 ± 0.89 0.000 0.31 ± 0.48 0.000
Right kidney Dmean (Gy) 3.34 ± 3.55 3.34 ± 3.55 3.36 ± 3.56 0.187 −0.03 ± 1.03 - 0.14 ± 0.76 - −0.17 ± 0.41 -
Bowl D2% (Gy) 11.87 ± 7.28 11.90 ± 7.32 11.98 ± 7.35 0.000 0.95 ± 0.87 0.000 0.81 ± 1.02 0.001 0.14 ± 0.94 0.206
Stomach D2% (Gy) 11.53 ± 8.30 11.65 ± 8.47 11.65 ± 8.40 0.000 0.78 ± 1.60 0.001 0.08 ± 1.95 0.031 0.70 ± 1.12 0.000
Spinal cord D2% (Gy) 9.92 ± 3.79 9.93 ± 3.79 9.95 ± 3.80 0.013 0.24 ± 1.18 0.010 0.21 ± 0.56 0.031 0.04 ± 0.77 0.081
Abbrevations: V21, the percentage liver volume received more than 21 Gy; Dmean, the mean dose; D2%, the minimum absorbed dose that covers 2% of the volume of a certain OAR. The others as in Table 2.
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the algorithm.
In conclusion, SBRT plans for treating liver cancer,
whether with VMAT or IMRT or 3D-CRT, are susceptible
to dose underestimations caused by contrast agent from
the PVP CT that are larger than those from the HAP CT
when compared with non-enhanced CT. Nevertheless, the
detection rate in HAP CT is higher than that in PVP CT
[9]. Therefore, it is still recommended HAP CT to be
applied for patient simulation in the treatment planning in
liver cancer.
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